Literature DB >> 7279800

Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC 82).

W Hoehn, F H Schroeder, J F Reimann, A C Joebsis, P Hermanek.   

Abstract

Transplantation of tissue from a cribriform human prostatic carcinoma resulted in a serially transplantable tumor line in nude mice, PC 82. During 2 1/2 years the tumor has not changed its histological appearance and remained a moderately differentiated adenocarcinoma. The cells contain large amounts of prostatic acid phosphatase. It has a slow rate of growth and regresses after castration and estrogen treatment. This preliminary information suggests that the PC 82 tumor line may be suitable model for hormone-dependent human prostatic cancer.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7279800     DOI： 10.1002/pros.2990010113

Source DB:  PubMed          Journal:  Prostate        ISSN： 0270-4137            Impact factor:   4.104


  27 in total

1.  Nuclear protein as a prognostic factor of growth activity in prostatic adenocarcinoma.

Authors:  G R Dohle; J A Beekhuis; G J van Steenbrugge; F H Schröder; H J Tanke
Journal:  Urol Res       Date:  1996

Review 2.  Human prostate cancer heterotransplants: a review on this experimental model.

Authors:  Lluis A Lopez-Barcons
Journal:  Asian J Androl       Date:  2010-04-05       Impact factor: 3.285

Review 3.  Human tumor xenografts as model for drug testing.

Authors:  J Mattern; M Bak; E W Hahn; M Volm
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

4.  Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Authors:  John T Isaacs; Jason M D'Antonio; Shuangling Chen; Lizamma Antony; Susan P Dalrymple; Georges H Ndikuyeze; Jun Luo; Samuel R Denmeade
Journal:  Prostate       Date:  2012-03-06       Impact factor: 4.104

5.  In vitro and in vivo model systems used in prostate cancer research.

Authors:  David Cunningham; Zongbing You
Journal:  J Biol Methods       Date:  2015

6.  A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

Authors:  Lawrence D True; Kent Buhler; Janna Quinn; Emily Williams; Peter S Nelson; Nigel Clegg; Jill A Macoska; Thomas Norwood; Alvin Liu; William Ellis; Paul Lange; Robert Vessella
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

7.  Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.

Authors:  Wennuan Liu; Chunmei Carol Xie; Yi Zhu; Tao Li; Jishan Sun; Yu Cheng; Charles M Ewing; Sue Dalrymple; Aubrey R Turner; Jielin Sun; John T Isaacs; Bao-Li Chang; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

8.  Unresponsiveness of the reproductive organs of the male mouse to treatment with a potent luteinizing hormone-releasing hormone agonist (ICI-118,630).

Authors:  G J van Steenbrugge; J C Romijn; F H de Jong; F H Schröder
Journal:  Urol Res       Date:  1984

9.  Effects of tumour mass and circulating antigen on the biodistribution of 111In-labelled F(ab')2 fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts.

Authors:  M Perälä-Heape; P Vihko; A Laine; J Heikkilä; R Vihko
Journal:  Eur J Nucl Med       Date:  1991

10.  Prostatic acid phosphatase in the serially transplantable human prostatic tumor lines PC-82 and PC-EW.

Authors:  Z Csapo; K Brand; K M Schrott; B Schwindl
Journal:  Urol Res       Date:  1990
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.